Search by Drug Name or NDC
NDC 49702-0264-23 Apretude Details
Apretude
Apretude is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ViiV Healthcare Company. The primary component is .
MedlinePlus Drug Summary
Cabotegravir and rilpivirine injections are used in combination for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain adults and children 12 years of age or older weighing at least 77 pounds (35 kg). Cabotegravir is in a class of medications called HIV integrase inhibitors. Rilpivirine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). These medications work by decreasing the amount of HIV in the blood. Although cabotegravir and rilpivirine do not cure HIV, they may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Receiving these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 49702-0264-23Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Cabotegravir and Rilpivirine Injections
Cabotegravir injection is used for prevention of human immunodeficiency virus type 1 (HIV-1) infection in certain adults and adolescents 12 years of age or older weighing at least 77 pounds (35 kg).
Related Packages: 49702-0264-23Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Cabotegravir injection
Product Information
| NDC | 49702-0264 |
|---|---|
| Product ID | 49702-264_e92b42ae-c037-4393-8547-c37c614a22b5 |
| Associated GPIs | 1210301000G120 |
| GCN Sequence Number | 082153 |
| GCN Sequence Number Description | cabotegravir SUSER VIAL 600 MG/3ML INTRAMUSC |
| HIC3 | W5U |
| HIC3 Description | ANTIVIRALS,HIV-1 INTEGRASE STRAND TRANSFER INHIBTR |
| GCN | 49487 |
| HICL Sequence Number | 047270 |
| HICL Sequence Number Description | CABOTEGRAVIR |
| Brand/Generic | Brand |
| Proprietary Name | Apretude |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Cabotegravir |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | KIT |
| Route | n/a |
| Active Ingredient Strength | n/a |
| Active Ingredient Units | n/a |
| Substance Name | n/a |
| Labeler Name | ViiV Healthcare Company |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA215499 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49702-0264-23 (49702026423)
| NDC Package Code | 49702-264-23 |
|---|---|
| Billing NDC | 49702026423 |
| Package | 1 KIT in 1 CARTON (49702-264-23) * 3 mL in 1 VIAL (49702-238-03) |
| Marketing Start Date | 2021-12-20 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |